Abbott Laboratories ABT

NYS: ABT | ISIN: US0028241000   24/06/2026
90,49 USD (-0,04%)
(-0,04%)   24/06/2026

24 juni 2026 · ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer's Disease Testing · Persbericht

22 juni 2026 · New Similac® survey finds social media pressure to be "perfect" is fueling a shift toward authenticity for the next generation of parents · Persbericht

12 juni 2026 · Abbott declares 410th consecutive quarterly dividend · Persbericht

8 juni 2026 · New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers · Persbericht

6 juni 2026 · New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis · Persbericht

27 mei 2026 · Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes · Persbericht

27 mei 2026 · ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening · Persbericht

26 mei 2026 · Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026 · Persbericht

28 april 2026 · Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform · Persbericht

25 april 2026 · Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026 · Persbericht

17 april 2026 · New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test · Persbericht

16 april 2026 · Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences · Persbericht

9 april 2026 · New survey finds most Americans believe chronic diseases are preventable, but only 1 in 4 feel confident in how to care for their health · Persbericht

30 maart 2026 · Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform · Persbericht

26 maart 2026 · Abbott hosts conference call for first-quarter earnings · Persbericht

24 maart 2026 · John Stamos and Jodie Sweetin reunite for "The (Second) Talk" with Cologuard® tests, encouraging colon cancer screening · Persbericht

23 maart 2026 · Abbott completes acquisition of Exact Sciences · Persbericht

20 maart 2026 · Abbott acquisition of Exact Sciences set to close on March 23, 2026 · Persbericht

12 maart 2026 · Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management · Persbericht

11 maart 2026 · Abbott and Real Madrid launch nationwide effort to build the next 'Abbott Dream Team' · Persbericht

Mijn selecties